Shinohara Yukito
Department of Internal Medicine and Neurology, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo, Japan.
Cerebrovasc Dis. 2006;22(1):57-60. doi: 10.1159/000092922. Epub 2006 Apr 26.
We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS). We now report the efficacy of this drug in the prevention of pneumonia in the chronic stage of cerebral infarction as a part of our CSPS subgroup analysis. The analysis was conducted in 1,049 subjects; 524 in the cilostazol group and 525 in the placebo group. The incidences of pneumonia during the 3.3-year follow-up were 2.86% (15 in 525 patients) in the placebo group and 0.57% (3 in 524 patients) in the cilostazol group, with a significant reduction in the cilostazol group. The rates of complications and pneumonia risk factors showed no difference between the two groups. We conclude that the administration of cilostazol to patients with cerebral infarction in the chronic stage does not only reduce the recurrence of infarction but also the incidence of pneumonia at least in Japanese patients.
我们之前曾报道，磷酸二酯酶抑制剂西洛他唑，一种抗血小板药物，对复发性脑梗死的二级预防有效且安全（西洛他唑预防卒中研究；CSPS）。作为我们CSPS亚组分析的一部分，我们现在报告这种药物在预防脑梗死慢性期肺炎方面的疗效。该分析在1049名受试者中进行；西洛他唑组524名，安慰剂组525名。在3.3年的随访期间，安慰剂组肺炎的发生率为2.86%（525例患者中有15例），西洛他唑组为0.57%（524例患者中有3例），西洛他唑组有显著降低。两组的并发症发生率和肺炎危险因素无差异。我们得出结论，至少在日本患者中，对慢性期脑梗死患者给予西洛他唑不仅能降低梗死复发率，还能降低肺炎发生率。
